Impact of CYP2C9, VKORC1, ApoE and ABCB1 Polymorphisms on Stable Warfarin Dose Requirements in Elderly Chinese Patients

References

• Ageno W , GallusAS , WittkowskyAet al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest141(Suppl. 2), e44S–e88S (2012).
   PubMed Web of Science ®Google Scholar
• Hirsh J , FusterV , AnsellJet al. American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J. Am. Coll. Cardiol.41(9), 1633–1652 (2003).
   PubMed Web of Science ®Google Scholar
• Wu J , WangJ , JiangSet al. The efficacy and safety of low intensity warfarin therapy in Chinese elderly atrial fibrillation patients with high CHADS2 risk score. Int. J. Cardiol.167(6), 3067–3068 (2013).
   PubMed Web of Science ®Google Scholar
• You JH , ChanFW , WongRSet al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br. J. Clin. Pharmacol. 59(5), 582–587 (2005).
   PubMed Web of Science ®Google Scholar
• Voora D , McLeodHL , EbyCet al. The pharmacogenetics of coumarin therapy. Pharmacogenomics6(5), 503–513 (2005).
   PubMed Web of Science ®Google Scholar
• Flora DR , RettieAE , BrundageRCet al. CYP2C9 genotype-dependent warfarin pharmacokinetics: impact of CYP2C9 genotype on R- and S-Warfarin and their oxidative metabolites. J. Clin. Pharmacol.57(3), 382–393 (2017).
   PubMed Web of Science ®Google Scholar
• Higashi MK , VeenstraDL , KondoLMet al. Association between CYP2C9 genetic variants and anticoagulationrelated outcomes during warfarin therapy. JAMA287(13), 1690–1698 (2002).
   PubMed Web of Science ®Google Scholar
• Rieder MJ , ReinerAP , GageBFet al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med.352(22), 2285–2293 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang W , ZhangWJ , ZhuJet al. Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics13(3), 309–321 (2012).
   PubMed Web of Science ®Google Scholar
• International Warfarin Pharmacogenetics Consortium , KleinTE , AltmanRBet al.Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360(8), 753–764 (2009).
   PubMed Web of Science ®Google Scholar
• Pautas E , MoreauC , Gouin-ThibaultIet al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther.87(1), 57–64 (2010).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY , ErikssonNet al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet.121, 23–34 (2007).
   PubMed Web of Science ®Google Scholar
• Bress A , PatelSR , PereraMAet al. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic–Americans and African-Americans. Pharmacogenomics13(16), 1925–1935 (2012).
   PubMed Web of Science ®Google Scholar
• Daneshjou R , GamazonER , BurkleyBet al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood124(14), 2298–2305 (2014).
   PubMed Web of Science ®Google Scholar
• Liang Y , ChenZ , GuoGet al. Association of genetic polymorphisms with warfarin dose requirements in Chinese patients. Genet. Test. Mol. Biomarkers17(12), 932–936 (2013).
   PubMed Web of Science ®Google Scholar
• Chung JE , ChangBC , LeeKEet al. Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. Eur. J. Clin. Pharmacol.71(10), 1229–1236 (2015).
   PubMed Web of Science ®Google Scholar
• Gu Q , KongY , SchneedeJet al. VKORC1-1639G>A, CYP2C9, EPHX-1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. Eur. J. Clin. Pharmacol.66(12), 1217–1227 (2010).
   PubMed Web of Science ®Google Scholar
• Tavares LC , MarcattoLR , SoaresRAGet al. Association between ABCB1 polymorphism and stable warfarin dose requirements in Brazilian patients. Front. Pharmacol.9, 542 (2018).
   PubMed Web of Science ®Google Scholar
• De Oliveira Almeida VC , DeSouza Ferreira AC , RibeiroDDet al. Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients. J. Thromb. Haemost.9(10), 2120–2012 (2011).
   PubMed Web of Science ®Google Scholar
• Kimmel SE , ChristieJ , KealeyCet al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J.8(1), 53–60 (2008).
   PubMed Web of Science ®Google Scholar
• Saupe J , ShearerMJ , KohlmeierM. Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am. J. Clin. Nutr.58(2), 204–208 (1993).
   PubMed Web of Science ®Google Scholar
• Lal S , SandanarajE , JadaSRet al. Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br. J. Clin. Pharmacol.65(2), 260–264 (2008).
   PubMed Web of Science ®Google Scholar
• Kaye JB , SchultzLE , SteinerHEet al. Warfarin pharmacogenomics in diverse populations. Pharmacotherapy37(9), 1150–1163 (2017).
   PubMed Web of Science ®Google Scholar
• Gan GG , PhippsME , LeeMMet al. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann. Hematol.90(6), 635–641 (2011).
   PubMed Web of Science ®Google Scholar
• Ross KA , BighamAW , EdwardsMet al. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J. Hum. Genet.55(9), 582–589 (2010).
   PubMed Web of Science ®Google Scholar
• Larramendy-Gozalo C , YangJQ , VerstuyftCet al. Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic Clin. Pharmacol. Toxicol.98(6), 611–613 (2006).
   PubMed Web of Science ®Google Scholar
• Yuan HY , ChenJJ , LeeMTet al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet.14(13), 1745–1751 (2005).
   PubMed Web of Science ®Google Scholar
• Sconce EA , DalyAK , KhanTIet al. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet. Genomics16(8), 609–611 (2006).
   PubMed Web of Science ®Google Scholar
• He S , ZhangH , CaoYet al. Association between apolipoprotein E genotype and warfarin response during initial anticoagulation. Biomed. Pharmacother.101, 251–256 (2018).
   PubMed Web of Science ®Google Scholar
• Liu R , ZhangK , GongZZet al. Association of apolipoprotein E (APOE) polymorphisms with warfarin maintenance dose in a northern Han Chinese population. Lipids Health Dis.15, 34 (2016).
   PubMed Web of Science ®Google Scholar
• Huang S , ChenB , XiangDet al. Association between apolipoprotein E gene polymorphism and the dose for warfarin maintenance. Zhong Nan Da Xue Xue Bao Yi Xue Ban.36(3), 212–216 (2011).
   PubMedGoogle Scholar
• Lepper ER , NooterK , VerweijJet al. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics6(2), 115–138 (2005).
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S , BurkO , von RichterOet al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7), 3473–3478 (2000).
   PubMed Web of Science ®Google Scholar
• Morita Y , SakaedaT , HorinouchiMet al. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm. Res.20(4), 552–556 (2003).
   PubMed Web of Science ®Google Scholar
• Sagreiya H , BerubeC , WenAet al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet. Genomics20(7), 407–413 (2010).
   PubMed Web of Science ®Google Scholar
• Lee MT , ChenCH , ChouCHet al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics10(12), 1905–1913 (2009).
   PubMed Web of Science ®Google Scholar
• Liu Y , YangJ , XuQet al. Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients. Thromb. Res.130(3), 435–440 (2012).
   PubMed Web of Science ®Google Scholar
• Lubitz SA , ScottSA , RothlaufEBet al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost.8(5), 1018–1026 (2010).
   PubMed Web of Science ®Google Scholar
• Tian L , ZhangJ , XiaoSet al. Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: systematic review and meta-analysis. Meta Gene5, 43–54 (2015).
   PubMedGoogle Scholar
• Liu HQ , ZhangCP , ZhangCZet al. Influence of two common polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis. Biomed. Res. Int.2015, 564149 (2015).
   PubMed Web of Science ®Google Scholar
• Lou Y , HanL , LiYet al. Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi.31(3), 367–371 (2014).
   PubMedGoogle Scholar
• Li J , YangW , XieZet al. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation. BMC Cardiovasc. Disord.18(1), 96 (2018).
   PubMedGoogle Scholar